Yada Kanjanapan
Yada Kanjanapan
Medical Oncology, The Canberra Hospital, Australia
Verified email at act.gov.au
Title
Cited by
Cited by
Year
Novel patterns of response under immunotherapy
E Borcoman, Y Kanjanapan, S Champiat, S Kato, V Servois, R Kurzrock, ...
Annals of Oncology 30 (3), 385-396, 2019
842019
Hyperprogressive disease in early‐phase immunotherapy trials: Clinical predictors and association with immune‐related toxicities
Y Kanjanapan, D Day, L Wang, H Al‐Sawaihey, E Abbas, A Namini, ...
Cancer 125 (8), 1341-1349, 2019
462019
Folic acid prevents and partially reverses glucocorticoid-induced hypertension in the rat
Y Miao, Y Zhang, PS Lim, Y Kanjanapan, TA Mori, KD Croft, J Earl, ...
American journal of hypertension 20 (3), 304-310, 2007
382007
Development and validation of prognostic nomograms for metastatic gastrointestinal stromal tumour treated with imatinib
CK Lee, D Goldstein, E Gibbs, H Joensuu, J Zalcberg, J Verweij, ...
European Journal of Cancer 51 (7), 852-860, 2015
252015
Niraparib for the treatment of ovarian cancer
Y Kanjanapan, S Lheureux, AM Oza
Expert opinion on pharmacotherapy 18 (6), 631-640, 2017
202017
Seamless designs: current practice and considerations for early-phase drug development in oncology
BP Hobbs, PC Barata, Y Kanjanapan, CJ Paller, J Perlmutter, GR Pond, ...
JNCI: Journal of the National Cancer Institute 111 (2), 118-128, 2019
162019
Delayed immune-related adverse events in assessment for dose-limiting toxicity in early phase immunotherapy trials
Y Kanjanapan, D Day, MO Butler, L Wang, AM Joshua, D Hogg, ...
European Journal of Cancer 107, 1-7, 2019
122019
Patterns of care for metastatic renal cell carcinoma in A ustralia
D Day, Y Kanjanapan, E Kwan, D Yip, N Lawrentschuk, M Andrews, ...
BJU international 116, 36-41, 2015
112015
Benefit from cytoreductive nephrectomy and the prognostic role of neutrophil‐to‐lymphocyte ratio in patients with metastatic renal cell carcinoma
D Day, Y Kanjanapan, E Kwan, D Yip, N Lawrentschuk, ID Davis, ...
Internal medicine journal 46 (11), 1291-1297, 2016
102016
Prognostic significance of KIT exon 11 deletion mutation in intermediate‐risk gastrointestinal stromal tumor
R Quek, M Farid, Y Kanjanapan, C Lim, IB Tan, S Kesavan, TKH Lim, ...
Asia‐Pacific Journal of Clinical Oncology 13 (3), 115-124, 2017
92017
Glut-1 expression in small cervical biopsies is prognostic in cervical cancers treated with chemoradiation
Y Kanjanapan, S Deb, RJ Young, M Bressel, L Mileshkin, D Rischin, ...
Clinical and translational radiation oncology 2, 53-58, 2017
62017
Hyperprogressive disease (HPD) in early-phase immunotherapy (IO) trials.
Y Kanjanapan, D Day, L Wang, AR Hansen, AR Abdul Razak, A Spreafico, ...
Journal of Clinical Oncology 36 (15_suppl), 3063-3063, 2018
52018
Phase II clinical and molecular trial of oral ENMD-2076 in clear cell ovarian cancer (CCOC): A study of the Princess Margaret phase II consortium.
S Lheureux, JV Burnier, Q Tan, Y Kanjanapan, B Clarke, A Tinker, ...
Journal of Clinical Oncology 35 (15_suppl), 5522-5522, 2017
52017
Immunologic and genomic characterization of high grade serous ovarian cancer (HGSOC) in patients (pts) treated with pembrolizumab (Pembro) in the phase II INSPIRE trial.
I Colombo, S Lien, C Yang, DL Clouthier, L Bonilla, S Cyriac, JL Ethier, ...
Journal of Clinical Oncology 35 (15_suppl), 5581-5581, 2017
32017
Acute ischaemic stroke following cisplatin-based chemotherapy for testicular cancer
Y Kanjanapan, D Gilbourd, G Pranavan
BMJ Case Reports CP 13 (5), e235005, 2020
12020
Survival in early phase immuno-oncology trials: development and validation of a prognostic index
D Day, C Guo, Y Kanjanapan, B Tran, A Spreafico, AM Joshua, L Wang, ...
JNCI Cancer Spectrum 3 (4), pkz071, 2019
12019
PS-139-Liver enzyme elevations and hepatotoxicity in patients treated with checkpoint inhibitor immunotherapy
M Cunningham, M Iafolla, Y Kanjanapan, O Cerocchi, M Butler, L Siu, ...
Journal of Hepatology 70 (1), e89, 2019
12019
Clinical trial of biopsies in oncology: Patient-reported impact (BIOPSY).
MK Wilson, S Lheureux, S Cyriac, NC Dhani, MO Butler, D Gutierrez, ...
Journal of Clinical Oncology 35 (15_suppl), e17034-e17034, 2017
12017
Phase II open-label randomized multi-centre study of neoadjuvant olaparib in patients (pts) with platinum sensitive (PS) relapsed high grade serous ovarian cancer (OC): The NEO …
Y Kanjanapan, S Lheureux, T May, MK Wilson, M Bernardini, PA Shaw, ...
Journal of Clinical Oncology 35 (15_suppl), TPS5608-TPS5608, 2017
12017
The challenge of managing adrenocortical carcinoma: two case studies
Y Kanjanapan, T Prasanna, S Perampalam, D Yip
International Journal of Endocrine Oncology 2 (3), 175-184, 2015
12015
The system can't perform the operation now. Try again later.
Articles 1–20